Investing

Praxis study halted for futility, other programs advance

BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is evaluating ...
Business Insider

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec.
Benzinga.com

Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate

On Friday, Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released interim data from Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET). The Independent Data Monitoring ...
Seeking Alpha

Praxis: Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts

The last time I spoke about Praxis Precision Medicines, Inc. (PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At that ...
Nasdaq

Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide

BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...